Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05124808 · ClinicalTrials.gov registry record · NA

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

A NA study of Overweight and Obesity and Gestational Diabetes, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
828
Enrollment target
5
Study locations

NCT05124808: Recruiting NA study of Overweight and Obesity and Gestational Diabetes, sponsored by Indiana University.

NCT05124808 is a NA study of Overweight and Obesity and Gestational Diabetes that is actively recruiting participants, run by Indiana University. The registered enrollment target is 828 participants, above the 221-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (275% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05124808, a NA study of Overweight and Obesity and Gestational Diabetes, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
828 participants
Enrollment target
5
Study locations

Study Summary

This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.

Primary Outcome

Composite of large for gestational age birth weight, neonatal hypoglycemia, neonatal jaundice, and neonatal respiratory distress syndrome

Interventions

  • OTHER Intensive glycemic targets
  • OTHER Standard glycemic targets

Study Locations (5)

Alabama

  • University of Alabama at Birmingham - Birmingham

Indiana

  • Indiana University - Indianapolis

Oklahoma

  • University of Oklahoma - Norman

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Rhode Island

  • Women and Infants Hospital of Rhode Island - Providence

Trial Details

FieldValue
Enrollment Target 828 participants
Start Date 2022-03-01
Est. Completion 2026-04-08
Phase NA
Indiana University

890 total trials

What NCT05124808 shows while recruiting

NCT05124808 is an interventional study that assigns participants to a tested intervention. The registered 828 participants enrollment target is mid-sized for trials with a published cap, above the 221-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (275% higher).

The record links to 3 conditions, with Overweight and Obesity appearing as the primary indexed condition, and to 2 interventions - of which Intensive glycemic targets is the first listed.

NCT05124808 lists 5 locations in 5 states (Alabama, Indiana, Oklahoma).

Frequently Asked Questions

What is clinical trial NCT05124808 about?

NCT05124808 is a clinical study titled "Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes". This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.

What is the current status of trial NCT05124808?

This trial is currently recruiting. It is a NA study. The enrollment target is 828 participants. The study started on 2022-03-01. Estimated completion is 2026-04-08.

What conditions does trial NCT05124808 study?

This clinical trial studies the following conditions: Overweight and Obesity, Gestational Diabetes, Pregnancy, High Risk.

What interventions are being tested in trial NCT05124808?

The interventions under investigation include: Intensive glycemic targets (OTHER), Standard glycemic targets (OTHER).

Who is sponsoring clinical trial NCT05124808?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05124808 being conducted?

This trial has 5 study locations across Alabama, Indiana, Oklahoma, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overweight and Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05124808's enrollment target sits among peer trials

828 6th of 115 higher than 110 of 115 other Overweight and Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Overweight and Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03547973 · 827 participants · Phase 2

    Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

  • NCT05067283 · 830 participants · Phase 1

    A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

  • NCT06592924 · 830 participants · Phase 3

    Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • NCT06868277 · 830 participants · Phase 3

    A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05124808, the US trial registry maintained by the National Library of Medicine. NCT05124808 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.